1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Phaarmasia Ltd.

Phaarmasia Ltd.

BBSE:PHRMASI
87.97
INR
0.00
(0.00%)
25.89EPS
3.86P/E
682.70MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
22.35
17.63
18.9
21.03
29.56
37.58
35.82
29.14
25.22
40.17
44.81
35.69
69.15
71.32
Basic EPS, GAAP
0.52
0.2
0.06
0.24
0.84
1.14
0.79
0.46
-2.27
-1.84
-0.76
-2.33
25.74
25.88
Free Cash Flow per Basic Share
-0.01
0.18
- -
-0.23
-0.03
-0.09
0.12
0.37
-0.26
0.95
0.16
-0.01
-24.04
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
10.91
19.2
16.84
17.08
17.61
18.77
19.64
20
17.66
15.83
15.08
12.8
32.37
- -
Tangible Book Value per Share
10.86
19.15
16.8
17.03
17.56
18.72
19.59
19.95
17.62
15.78
15.04
12.75
32.32
- -
Basic Weighted Avg Shares
7
7
7
7
7
7
7
7
7
7
7
7
7
7
Sales/Revenue/Turnover
152
123
132
144
202
257
245
199
172
275
306
244
472
486
Operating Margin (%)
3.56
1.63
-2.12
-2.15
0.95
1.03
1.72
-2.03
-11.78
-6.92
-3.8
-9.57
3.52
3.38
Depreciation Expense
4
8
5
4
5
5
4
3
3
4
3
3
2
2
Net Income, GAAP
4
1
- -
2
6
8
5
3
-15
-13
-5
-16
176
176
Effective Tax Rate (%)
19.05
61.63
82.95
38.98
15.68
6.45
43.81
34.83
- -
- -
- -
- -
17.84
17.48
Profit Margin (%)
2.33
1.13
0.32
1.13
2.84
3.03
2.21
1.57
-8.99
-4.58
-1.69
-6.52
37.22
36.29
Working Capital
-30
-24
-20
-15
-16
-6
5
7
-6
-22
-29
-44
190
- -
LT Debt
- -
1
1
- -
1
2
1
- -
- -
2
- -
- -
- -
- -
Total Equity
74
131
115
117
120
128
134
137
121
108
103
87
221
- -
Return on Invested Capital (%)
4.67
1.33
0.33
1.35
1.34
2.16
1.73
-1.9
- -
- -
- -
- -
95.18
- -
Return on Capital (%)
4.95
1.47
0.35
1.44
5.08
6.39
4.21
2.34
- -
- -
- -
- -
110.83
- -
Return on Common Equity (%)
4.71
1.36
0.34
1.4
4.84
6.26
4.12
2.31
-12.03
-11.01
-4.91
-16.7
113.99
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
11
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
770
513
683

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
267
- -
Cash, Cash Equivalents & STI
- -
110
- -
Accounts Receivable, Net
- -
51
- -
Inventories
- -
44
- -
Total Current Liabilities
- -
77
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
11
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.86%
22.2%
152.95%
Free Cash Flow
44,711.08%
90,986.64%
455,761.11%
Net Income, GAAP
-116.76%
-334.46%
-1,205.62%
Sales/Revenue/Turnover
18.44%
26.17%
93.72%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
83
59
47
54
244
2026
69
166
161
77
472
2027
83
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.4
-0.94
-1.02
-0.77
-2.33
2026
0.4
2.54
23.84
-1.03
25.74
2027
0.5
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yallapragada Naga Bhaskara Rao
Full Time Employees
47
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Plot No. 16 Hyderabad TS India 500055
IPO Date
Jul 27, 1992
Website
phaarmasia.in
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Phaarmasia Limited manufactures and sells pharmaceutical products including oral contraceptive pills and iron tablets in India; hormone products such as mifepristone and misoprostol, desogestrel and ethinyl estradiol, estradiol valerate, levonorgestrel and ethinyl estradiol, medroxyprogesterone acetate, cabergoline, clomiphene citrate, levonorgestrel, progesterone, fluoxymesterone, liothyronine sodium, chlorodehydromethyltestosterone, oxandrolone tablets, testosterone cypionate, methenolone enanthate, drostanolone, testosterone, trenbolone, and stanozolol cypionate injections; and herbal products including herbal toothpaste, cough and sore throat reliever, and mouth ulcer gel under the Smyle brand name. The company, founded in 1981 and headquartered in Hyderabad, Telangana, India, operates primarily in the pharmaceuticals sector with a focus on hormonal, steroidal, and oral care formulations for domestic markets including supplies to the Ministry of Health & Family Welfare and exports. In recent developments, Phaarmasia reported a net profit of Rs 1.74 crore for the quarter ended September 2025, reflecting a turnaround from prior losses amid sales growth of 179% to Rs 16.55 crore year-over-year; the board approved unaudited financial results in board meetings held in August, November, and May 2025, alongside scheduling the 44th annual general meeting and reappointing directors with increased remuneration; and shareholding patterns remained stable with promoters holding 73.51% as of June 2025.